Evogene (EVGN)
0.54
0.00 (0.00%)
Upcoming Events
Latest Headlines
Evogene and ELEO team up on oral PCSK9 inhibitor discovery
July 22, 2026 8:02 AM - StreetInsider
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
July 22, 2026 8:00 AM - PR NewsWire
Form SCHEDULE 13D/A Evogene Ltd. Filed by: L.I.A. Pure Capital Ltd
July 20, 2026 3:47 PM - SEC Filing
Form 424B5 Evogene Ltd.
July 17, 2026 4:06 PM - SEC Filing
Form 6-K Evogene Ltd. For: Jul 17
July 17, 2026 4:03 PM - SEC Filing
AgPlenus launches AI model to predict antifungal potency
July 15, 2026 7:31 AM - StreetInsider
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
July 15, 2026 7:30 AM - PR NewsWire
EverGen Infrastructure Announces Record RNG Production for Q2 2026
July 14, 2026 4:05 PM - BizWire
Form SCHEDULE 13D Evogene Ltd. Filed by: L.I.A. Pure Capital Ltd
July 10, 2026 9:27 AM - SEC Filing
Evogene and Tel Aviv University partner on AI drug discovery
July 8, 2026 7:01 AM - StreetInsider
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
July 8, 2026 7:00 AM - PR NewsWire
EverGen Infrastructure Announces Share Issuance to Officers and Directors of the Company
July 6, 2026 11:00 PM - BizWire
Evogene integrates Google Cloud AI agents into its ChemPass platform
June 24, 2026 8:01 AM - StreetInsider
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
June 24, 2026 8:00 AM - PR NewsWire
Form 6-K Evogene Ltd. For: Jun 16
June 16, 2026 7:00 AM - SEC Filing
Form 424B5 Evogene Ltd.
June 11, 2026 4:06 PM - SEC Filing
Form 6-K Evogene Ltd. For: Jun 11
June 11, 2026 4:01 PM - SEC Filing
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
June 9, 2026 7:00 AM - PR NewsWire
Evogene completes phase 1 trial of bacterial cancer treatment BMC128
June 2, 2026 7:00 AM - StreetInsider
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
June 2, 2026 7:00 AM - PR NewsWire
EverGen Infrastructure Reports Q1 2026 Results
May 28, 2026 5:57 PM - BizWire
Form 424B3 Evogene Ltd.
May 20, 2026 8:46 AM - SEC Filing
Evogene (EVGN) Tops Q1 EPS by 26c
May 20, 2026 7:03 AM - StreetInsider
Form 6-K Evogene Ltd. For: May 20
May 20, 2026 7:00 AM - SEC Filing
Evogene Reports First Quarter 2026 Financial Results
May 20, 2026 7:00 AM - PR NewsWire
Form 6-K Evogene Ltd. For: May 18
May 18, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13G Evogene Ltd. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:17 AM - SEC Filing
Evogene to Present at the 24th Schrödinger European User Group Meeting
May 12, 2026 8:00 AM - PR NewsWire
Evogene Schedules First Quarter 2026 Financial Results Release
May 7, 2026 8:00 AM - PR NewsWire
EverGen Infrastructure Reports Q4 & Year End 2025 Results
April 29, 2026 7:46 PM - BizWire
Full Article List
